Nanocovax

Nanocovax is a COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC, a Vietnam-based biopharmaceutical company. The vaccine is currently in the late-stage clinical trials and is one of the few vaccines developed using the protein subunit approach.

Development

The development of Nanocovax began in May 2020, when the COVID-19 pandemic was at its peak. The vaccine is based on the recombinant protein technology, which involves the use of a harmless piece of the virus to trigger an immune response in the body. This technology is considered safe and has been used in several other vaccines, including the Hepatitis B vaccine and the HPV vaccine.

Clinical Trials

Nanocovax has undergone three phases of clinical trials. The first phase began in December 2020 and involved 60 participants. The second phase started in February 2021 with 560 participants, and the third phase started in June 2021 with around 13,000 participants. The results from the first two phases showed that the vaccine was safe and produced a strong immune response.

Efficacy

The efficacy of Nanocovax is yet to be confirmed as the third phase of clinical trials is still ongoing. However, preliminary results from the first two phases suggest that the vaccine could have an efficacy rate of over 90%.

Distribution

Once approved, Nanocovax is expected to be distributed domestically in Vietnam and exported to other countries. The company has the capacity to produce up to 120 million doses per year.

See Also

• COVID-19 pandemic
• COVID-19 vaccine
• Nanogen Pharmaceutical Biotechnology JSC
• Protein subunit
• Clinical trials

Error creating thumbnail:

   This article is a  stub. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!